Anstee, Quentin M.

Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis

Petta, S., Sebastiani, G., Bugianesi, E., Viganò, M., Wong, V. W.-S., Berzigotti, A., Fracanzani, A. L., Anstee, Q. M., Marra, F., Barbara, M., et al. (2018) · Journal of Hepatology

Liver Disease and TransplantationLiver Disease Diagnosis and Treatment

Cited by 140

Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis

Sanyal, A. J., Ratziu, V., Loomba, R., Anstee, Q. M., Kowdley, K. V., Rinella, M. E., Sheikh, M. Y., Trotter, J. F., Knapple, W., Lawitz, E. J., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 137

Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis

Loomba, R., Ratziu, V., Harrison, S. A., Loomba, R., McFarlane, S. C., Tamaki, N., Ratziu, V., Abdelmalek, M. F., Rinella, M. E., Anstee, Q. M., et al. (2022) · Gastroenterology

Liver Disease Diagnosis and TreatmentStatistical Methods in Clinical Trials

Cited by 127

Serum Immunoglobulin Levels Predict Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease

McPherson, S., Henderson, E., Burt, A. D., Day, C. P., & Anstee, Q. M. (2014) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 124

Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study

Isokuortti, E., Zhou, Y., Peltonen, M., Bugianesi, E., Clement, K., Bonnefont-Rousselot, D., Lacorte, J.-M., Gastaldelli, A., Schuppan, D., Schattenberg, J. M., et al. (2017) · Diabetologia

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 120

The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis

Younossi, Z. M., Anstee, Q. M., Wai-Sun Wong, V., Trauner, M., Lawitz, E. J., Harrison, S. A., Camargo, M., Kersey, K., Subramanian, G. M., Myers, R. P., et al. (2021) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 118

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis

Loomba, R., Huang, D. Q., Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Ding, D., Ma, L., Jia, C., Billin, A., et al. (2023) · Gut

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 110

Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling

Kotsiliti, E., Leone, V., Schuehle, S., Govaere, O., Li, H., Wolf, M. J., Horvatic, H., Bierwirth, S., Hundertmark, J., Inverso, D., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 108

Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis

Lee, J., Vali, Y., Boursier, J., Duffin, K., Verheij, J., Brosnan, M. J., Zwinderman, K., Anstee, Q. M., Bossuyt, P. M., & Zafarmand, M. H. (2020) · PLOS ONE

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 74

Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis

Jarvis, H., O'Keefe, H., Craig, D., Stow, D., Hanratty, B., & Anstee, Q. M. (2022) · BMJ Open

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 71

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

Martínez‐Arranz, I., Bruzzone, C., Noureddin, M., Gil‐Redondo, R., Mincholé, I., Bizkarguenaga, M., Arretxe, E., Iruarrizaga‐Lejarreta, M., Fernández‐Ramos, D., Lopitz‐Otsoa, F., et al. (2022) · Hepatology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 65

Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis

Vacca, M., Leslie, J., Virtue, S., Lam, B. Y. H., Govaere, O., Tiniakos, D., Snow, S., Davies, S., Petkevicius, K., Tong, Z., et al. (2020) · Nature Metabolism

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 60

Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with nonalcoholic fatty liver disease

Rosso, C., Caviglia, G. P., Birolo, G., Armandi, A., Pennisi, G., Pelusi, S., Younes, R., Liguori, A., Perez-Diaz-del-Campo, N., Nicolosi, A., et al. (2023) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 59

NAFLD and NASH biomarker qualification in the LITMUS consortium – Lessons learned

Rasmussen, D. G. K., Anstee, Q. M., Torstenson, R., Golding, B., Patterson, S. D., Brass, C., Thakker, P., Harrison, S., Billin, A. N., Schuppan, D., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentStatistical Methods in Clinical Trials

Cited by 41

Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials

Wong, V. W.-S., Tak, W. Y., Goh, G. B. B., Cheng, P.-N., Lawitz, E. J., Younossi, Z. M., Vuppalanchi, R., Younes, Z., Alkhouri, N., Wang, L., et al. (2023) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 31

Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease

Sen, P., Govaere, O., Sinioja, T., McGlinchey, A., Geng, D., Ratziu, V., Bugianesi, E., Schattenberg, J. M., Vidal-Puig, A., Allison, M., et al. (2022) · iScience

Liver Disease Diagnosis and TreatmentMetabolomics and Mass Spectrometry Studies

Cited by 28

Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors

Cazanave, S. C., Warren, A. D., Pacula, M., Touti, F., Zagorska, A., Gural, N., Huang, E. K., Sherman, S., Cheema, M., Ibarra, S., et al. (2021) · Science Translational Medicine

Liver Disease Diagnosis and TreatmentAdvanced Proteomics Techniques and Applications

Cited by 23

SAT-214 Using machine learning models to predict baseline fibrosis stage in patients from phase 3 resmetirom trials (MAESTRO-NAFLD and MAESTRO-NASH)

Schattenberg, J. M., Anstee, Q. M., Harrison, S. A., Noureddin, M., Taub, R., Labriola, D., Priel, J., & Padmanabhan, K. (2024) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentRadiomics and Machine Learning in Medical Imaging

Cited by 1